

# Results From the AD-GAP Survey – A Qualitative Analysis of Patient/Caregiver/Physician's Perceptions on the Impact of Moderate-to-Severe Atopic Dermatitis in Children and Adolescents

Stephan Weidinger<sup>1</sup>, Korey Capozza<sup>2</sup>, Andrew E. Pink<sup>3</sup>, Mark Tang<sup>4</sup>, Marjorie Leclerc<sup>5</sup>, Randy Prescilla<sup>6</sup>, Amy S. Paller<sup>7,8</sup>

<sup>1</sup>University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; <sup>2</sup>Global Parents for Eczema Research, Santa Barbara, CA, USA; <sup>3</sup>St. John's Institute of Dermatology, Guy's & St. Thomas' Hospitals, London, UK; <sup>4</sup>Mount Alvernia Medical Centre, Singapore; <sup>5</sup>Kantar Health, Paris, France; <sup>6</sup>Sanofi Genzyme, Cambridge, MA, USA; <sup>7</sup>Northwestern University Feinberg School of Medicine, Chicago, IL, USA; <sup>8</sup>Ann and Robert H. Lurie Children's Hospital, Chicago, IL, USA

## BACKGROUND

- The AD Global Adolescent and Pediatric (AD-GAP) survey is a global, qualitative and quantitative survey of children and adolescents with moderate-to-severe AD, their caregivers, and treating physicians; it is designed to obtain a deeper understanding of the patients', caregivers', and physicians' day-to-day experience of AD

## OBJECTIVE

- To determine the disease burden of AD from the perspectives of the patients, caregivers, and physicians and to identify any differences in their perceptions

## METHODS

### Study design and participants

- The AD-GAP survey comprises a targeted qualitative research approach and subsequent quantitative research; here, we report results from the qualitative part of the survey
- The qualitative study enrolled 36 children (6–11 years) and 36 adolescents (12–17 years) (moderate AD, n = 45; severe AD, n = 27); and 1 caregiver and 1 physician per patient
  - Physicians were 27 dermatologists, 24 pediatricians, 16 general practitioners, and 5 allergists
- Patients, caregivers, and physicians were recruited from 12 countries across 4 continents
- Patients/caregivers/physicians participated in individual in-depth interviews and completed similar questionnaires by rating different quality-of-life (QoL) aspects on a 5-point scale; patients also completed age-appropriate booklet activities to help them verbalize their perceptions during the interview

## RESULTS

Figure 1. Patients (children/adolescents): most bothersome aspects of AD.





Figure 2. Caregivers: main concerns regarding their child's AD.



## CONCLUSIONS

- Patients, their caregivers, and physicians broadly acknowledge that moderate-to-severe AD affects the QoL of patients and their families
- However, there are qualitative differences between their perceptions, which will be further investigated in the subsequent quantitative part of the survey
- Addressing these differences may help improve communication between physicians, patients, and caregivers, leading to better disease management and outcomes

Figure 3. Physicians: the challenges of treating AD.




Figure 4. Summary of the overall perception of AD by patients, caregivers, and physicians.



**Acknowledgments:** Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. Medical writing/editorial assistance was provided by Excerpta Medica, and was funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline.

**Disclosures:** Weidinger S: LEO Pharma, L'Oréal, Novartis, Pfizer – research grants; AbbVie, Eli Lilly, Galderma, Incyte, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme – consultant; AbbVie, Eli Lilly, LEO Pharma, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme – speaker fees. Capozza K: Incyte, Sanofi – consultant; Dermira, Sanofi – investigator. Pink AE: AbbVie, Almirall, Eli Lilly, Janssen, La Roche-Posay, LEO Pharma, Novartis, Sanofi, UCB – consultant, speaker; AbbVie, Janssen, UCB – investigator. Tang M: Bioderma, Galderma, GSK, Hyphens Pharma, Kao, LEO Pharma, Menarini, Regeneron Pharmaceuticals, Inc., Sanofi – speaker honoraria, advisory board member. Leclerc M: Kantar Health – employee. Prescilla R: Sanofi Genzyme – employee, may hold stock and/or stock options in the company. Paller AS: AbbVie, AnaptysBio, Eli Lilly, Incyte, Janssen, Lenus Pharma, LEO Pharma, Novartis, Regeneron Pharmaceuticals, Inc., UCB – investigator; AbbVie, Abeona Therapeutics, Almirall, Asana BioSciences, Boehringer Ingelheim, BridgeBio, Dermavant, Dermira, Eli Lilly, Excicure, Forté, Galderma, Incyte, InMed Pharmaceuticals, Janssen, LEO Pharma, LifeMax, Novartis, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Sol-Gel, UCB – consultant.

Presented at the 46th Annual Meeting of the Society for Pediatric Dermatology (SPD 2021); Virtual Meeting; July 8–10, 2021.